Dikhyaa Mohanty 
Not just in India but in many other nations as well, dengue is becoming a more serious threat. Since there is no particular cure for the vector-borne illness, it is concerning. There is, however, cause for optimism as a Johnson & Johnson dengue fever medication has been discovered to shield a limited number of patients against a strain of the virus in a tiny human challenge experiment conducted in the United States, according to Reuters. Prior to presenting the research at the American Society of Tropical Medicine and Hygiene Annual Meeting in Chicago, the business stated that there are presently no particular medicines for dengue, an increasingly serious disease concern.
According to Marnix Van Loock, who is in charge of J & J’s Janssen division’s research on emerging infections, the medication “is the first ever to show antiviral activity against dengue.” In a human challenge trial, a pathogen is purposefully exposed to healthy volunteers in order to test a therapy or vaccination, or to learn more about the disease the pathogen causes. Five days before to receiving an injection with a particular strain of dengue, ten participants in the J&J experiment conducted in collaboration with the Johns Hopkins Bloomberg School of Public Health received a high dosage of the dengue pill. After that, they kept taking the medication for another 21 days.
After being exposed to the pathogen, six out of the ten had no detectable dengue virus in their blood, and after 85 days of observation, they also exhibited no indication that their immune system had reacted to the viral infection. Test results for six individuals in a placebo group who also received dengue injections revealed detectable virus.
The early data, which was presented on Friday at the annual conference of the American Society of Tropical Medicine and Hygiene in Chicago, is encouraging and supports the continuing Phase 2 trials of the tablet to prevent four different forms of dengue in an environment where the illness is prevalent. According to J & J, evaluating it as a therapy will be the next step.
The medication stops the activity of two viral proteins, which stops the virus from replicating, according to the business. Every everyone included in the experiment tolerated it well. Each year, millions of illnesses and thousands of fatalities occur in Asia and Latin America. Chief scientist Jeremy Farrar of the World Health Organization (WHO) predicts that it will likely spread farther as a result of climate change making more places conducive for mosquitoes that transmit it.
